KYMR - NASDAQ

Kymera Therapeutics, Inc.

KYMR·NASDAQ

$73.25

+0.77%

HealthcareBiotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.03B

EPS-3.6900

P/E Ratio-19.85

Earnings Date08/10/2026

kymr

Sales/Maturities of Investments

Last Annual Value

479.14M

3-Year CAGR

5-Year CAGR

33%

10-Year CAGR

Adjust for Inflation

Kymera Therapeutics, Inc. Competitors Analysis of Sales/Maturities of Investments

KYMR · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Kymera Therapeutics, Inc. NASDAQ:KYMR	479.14M	N/A	6.0%	N/A
Immunovant, Inc. NASDAQ:IMVT	0.00	N/A	N/A	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	759.42M	36.4%	29.8%	43.9%
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	1.18B	52.0%	76.4%	N/A
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	122.06M	N/A	N/A	N/A
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD	493.53M	3.7%	3.1%	1.4%
Arcellx, Inc. NASDAQ:ACLX	495.60M	17.0%	N/A	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	254.07M	N/A	N/A	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	407.33M	24.8%	36.5%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	312.72M	100.2%	66.1%	N/A

Kymera Therapeutics, Inc. Fair Value Envelope

KYMR · NASDAQ

Our analysis suggests that KYMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $73.25, this represents a potential HIDDEN relative to our calculated worth for Kymera Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $73.25

Related Guides

Blog Categories

Continue your KYMR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.